Dublin, June 26, 2019 (GLOBE NEWSWIRE) -- The "Market Spotlight: Fragile X Syndrome" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Fragile X Syndrome market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, recent events and analyst opinion, a discussion on disease epidemiology, and licensing and asset acquisition deals.

Key Takeaways

• Based on cohorts of children with special educational needs, prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females.
• The majority of the industry-sponsored drugs in active clinical development for FXS are in Phase II, with only one drug in Phase III.
• Therapies in mid- and late-stage development focus on targets such as cannabinoid-1/cannabinoid-2 receptor, phosphodiesterase 4, insulin-like growth factor-1 receptor, and GABA-A receptor. The majority of the pipeline drugs are administered via the oral and intravenous routes, while one drug is available in a topical formulation.
• High-impact upcoming events in the FXS space comprise topline Phase III trial results for ZYN-002, and topline Phase II trial results for OV101.
• The overall likelihood of approval of a Phase I neurodevelopmental disorders asset is 4.8%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 8.3 years from Phase I to approval, compared to 9.6 years in the overall neurology space.
• There have been five licensing and asset acquisition deals involving FXS drugs during 2014-19. The exclusive licensing agreement in 2017 between Boehringer Ingelheim and Autifony Therapeutics, worth $737.5m, for a collaboration on a novel therapeutic approach to a range of CNS disorders, was the largest deal during the period.
• All clinical trials for FXS have been in Phase II, with no Phase III trials to date.
• The US leads in terms of the number of FXS clinical trials globally.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• ZYN-002 for FXS (September 28, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Shionogi Picks Up Asia Rights To Tetra's Cognitive Candidate

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Overview of pipeline drugs for FXS in the US
Figure 2: Pipeline drugs for FXS, by company
Figure 3: Pipeline drugs for FXS, by drug type
Figure 4: Pipeline drugs for FXS, by classifications
Figure 5: ZYN-002 for FXS (September 28, 2017): Phase II - FAB-C
Figure 6: Key upcoming events in FXS
Figure 7: Probability of success in the FXS pipeline
Figure 8: Licensing and asset acquisition deals in FXS, 2014-19
Figure 9: Parent patents in FXS
Figure 10: Clinical trials in FXS
Figure 11: Top 10 drugs for clinical trials in FXS
Figure 12: Top 10 companies for clinical trials in FXS
Figure 13: Trial locations in FXS
Figure 14: FXS trials status
Figure 15: FXS trials sponsors, by phase

LIST OF TABLES
Table 1: Pipeline drugs for FXS in the US
Table 2: ZYN-002 for FXS (September 28, 2017)

For more information about this report visit https://www.researchandmarkets.com/r/e1gsa5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs , Neurology

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.